Analyze Diet
FEMS immunology and medical microbiology1998; 22(1-2); 163-168; doi: 10.1111/j.1574-695X.1998.tb01201.x

Animal models of pneumocystosis.

Abstract: As in vitro culture systems allowing to isolate Pneumocystis samples from patients or other mammal hosts are still not available, animal models have critical importance in Pneumocystis research. The parasite was reported in numerous mammals but P. carinii pneumonia (PCP) experimental models were essentially developed by using rats, mice, rabbits and ferrets. The rat treated with corticosteroids for 9-12 weeks is a useful PCP model. Like laboratory rats, conventional mice develop PCP after prolonged corticosteroid administration. The ferret (Mustela putorius furo) also develop PCP under corticosteroid regime. Whilst bronchoalveolar lavage (BAL) is really difficult to perform on live laboratory rodents, serial BAL sampling can be performed on live ferrets. Rabbits currently develop spontaneous PCP at weaning without corticosteroid administration. For this reason this model has been used for studying the host immune response as well as Pneumocystis-surfactant interactions. Pigs and horses also develop spontaneous PCP. Treated with corticosteroids, piglets develop extensive PCP and could be used as a non-rodent model. Pneumocystis was detected in many non-human primates. Primates could represent a source of parasites taxonomically related to P. carinii sp. f. hominis. Moreover, primates might be used as experimental hosts to human Pneumocystis. A marked variability of parasite levels among corticosteroid-treated animals and the fact that the origin of the parasite strain remains unknown, are important drawbacks of the corticosteroid-treated models. For these reasons, inoculated animal models of PCP were developed. The intratracheal inoculation of lung homogenates containing viable parasites in corticosteroid-treated non-latently infected rats resulted in extensive, reproducible Pneumocystis infections. Extensive PCP can be obtained within 5-7 weeks, whilst 9-12 weeks are needed in the classical model. The severe combined immunodeficiency (SCID) mouse inoculated by nasal route and the athymic nude rats intratracheally inoculated were used to test the infectivity of Pneumocystis samples coming from cultures or from different hosts. They were also used to test the anti-Pneumocystis activity of antimicrobial molecules.
Publication Date: 1998-10-29 PubMed ID: 9792075DOI: 10.1111/j.1574-695X.1998.tb01201.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research discusses the importance of animal models in studying Pneumocystis- a type of fungal infection often seen in immunocompromised individuals. Scientists primarily use rats, mice, rabbits and ferrets for developing these models. Variability in parasite levels and unknown origin of parasite strains present challenges. Therefore, inoculated animal models are being developed for more predictable research outcomes.

Importance of Animal Models in Pneumocystis Research

  • As no in vitro culture systems exist for isolating Pneumocystis samples from patients or hosts, animal models become essential for studying the disease.
  • Various mammals such as rats, mice, rabbits and ferrets have been used in developing experimental models of Pneumocystis carinii pneumonia (PCP), a type of pneumocystosis.

Use of Different Animals in PCP Models

  • Rats and mice treated with corticosteroids are commonly used in PCP models. Rabbits develop spontaneous PCP at weaning, providing a way to study host immune responses and interactions between Pneumocystis and lung surfactants.
  • Other animals such as pigs, horses and ferrets also develop this disease, with ferrets being particularly useful for bronchoalveolar lavage (BAL) sampling, as it is difficult to perform on live rodents.
  • These animals, when treated with corticosteroids, serve as valuable, non-rodent models for studying PCP.

Challenges in Using Corticosteroid-Treated Models

  • While treating animals with corticosteroids can induce Pneumocystis infections, there exists a significant variability in parasite levels among treated animals.
  • The source of the Pneumocystis strain used in these experiments often remains unknown.

Use of Inoculated Animal Models

  • To overcome these challenges, inoculated animal models of PCP were developed, involving the intratracheal inoculation of lung homogenates containing parasites in corticosteroid-treated non-latently infected rats.
  • This technique results in more reproducible and extensive Pneumocystis infections.
  • Severe combined immunodeficiency (SCID) mice and athymic nude rats were also used for testing the infectivity of Pneumocystis samples from different hosts.

Cite This Article

APA
Dei-Cas E, Brun-Pascaud M, Bille-Hansen V, Allaert A, Aliouat EM. (1998). Animal models of pneumocystosis. FEMS Immunol Med Microbiol, 22(1-2), 163-168. https://doi.org/10.1111/j.1574-695X.1998.tb01201.x

Publication

ISSN: 0928-8244
NlmUniqueID: 9315554
Country: England
Language: English
Volume: 22
Issue: 1-2
Pages: 163-168

Researcher Affiliations

Dei-Cas, E
  • Faculty of Medicine and Regional University Hospital Centre, Lille, France. eduardo.dei-cas@pasteur-lille.fr
Brun-Pascaud, M
    Bille-Hansen, V
      Allaert, A
        Aliouat, E M

          MeSH Terms

          • Animals
          • Disease Models, Animal
          • Humans
          • Pneumonia, Pneumocystis

          Citations

          This article has been cited 20 times.
          1. Albrecht RA, Liu WC, Sant AJ, Tompkins SM, Pekosz A, Meliopoulos V, Cherry S, Thomas PG, Schultz-Cherry S. Moving Forward: Recent Developments for the Ferret Biomedical Research Model.. mBio 2018 Jul 17;9(4).
            doi: 10.1128/mBio.01113-18pubmed: 30018107google scholar: lookup
          2. Aliouat EM, Dei-Cas E, Gantois N, Pottier M, Pinçon C, Hawser S, Lier A, Huang DB. In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.. Eur J Clin Microbiol Infect Dis 2018 Mar;37(3):409-415.
            doi: 10.1007/s10096-018-3184-zpubmed: 29330709google scholar: lookup
          3. Hohl TM. Overview of vertebrate animal models of fungal infection.. J Immunol Methods 2014 Aug;410:100-12.
            doi: 10.1016/j.jim.2014.03.022pubmed: 24709390google scholar: lookup
          4. Martinez A, Halliez MC, Aliouat el M, Chabé M, Standaert-Vitse A, Fréalle E, Gantois N, Pottier M, Pinon A, Dei-Cas E, Aliouat-Denis CM. Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii.. PLoS One 2013;8(11):e79958.
            doi: 10.1371/journal.pone.0079958pubmed: 24223207google scholar: lookup
          5. Can H, Caner A, Döşkaya M, Değirmenci A, Karaçalı S, Polat C, Gürüz Y, Uner A. Detection of Pneumocystis in the nasal swabs of immune-suppressed rats by use of PCR and microscopy.. Med Sci Monit Basic Res 2013 Feb 13;19:62-7.
            doi: 10.12659/MSMBR.883777pubmed: 23403744google scholar: lookup
          6. Kling HM, Shipley TW, Patil SP, Kristoff J, Bryan M, Montelaro RC, Morris A, Norris KA. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection.. Infect Immun 2010 Oct;78(10):4320-30.
            doi: 10.1128/IAI.00507-10pubmed: 20660609google scholar: lookup
          7. Keely SP, Stringer JR. Complexity of the MSG gene family of Pneumocystis carinii.. BMC Genomics 2009 Aug 7;10:367.
            doi: 10.1186/1471-2164-10-367pubmed: 19664205google scholar: lookup
          8. Keely SP, Linke MJ, Cushion MT, Stringer JR. Pneumocystis murina MSG gene family and the structure of the locus associated with its transcription.. Fungal Genet Biol 2007 Sep;44(9):905-19.
            doi: 10.1016/j.fgb.2007.01.004pubmed: 17320432google scholar: lookup
          9. Chabé M, Dei-Cas E, Creusy C, Fleurisse L, Respaldiza N, Camus D, Durand-Joly I. Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication.. Eur J Clin Microbiol Infect Dis 2004 Feb;23(2):89-97.
            doi: 10.1007/s10096-003-1092-2pubmed: 14712369google scholar: lookup
          10. Norris KA, Wildschutte H, Franko J, Board KF. Genetic variation at the mitochondrial large-subunit rRNA locus of Pneumocystis isolates from simian immunodeficiency virus-infected rhesus macaques.. Clin Diagn Lab Immunol 2003 Nov;10(6):1037-42.
          11. Thullen TD, Ashbaugh AD, Daly KR, Linke MJ, Steele PE, Walzer PD. New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.. Infect Immun 2003 Nov;71(11):6292-7.
          12. Coutte L, Alonso S, Reveneau N, Willery E, Quatannens B, Locht C, Jacob-Dubuisson F. Role of adhesin release for mucosal colonization by a bacterial pathogen.. J Exp Med 2003 Mar 17;197(6):735-42.
            doi: 10.1084/jem.20021153pubmed: 12629063google scholar: lookup
          13. Larsen HH, Kovacs JA, Stock F, Vestereng VH, Lundgren B, Fischer SH, Gill VJ. Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii.. J Clin Microbiol 2002 Aug;40(8):2989-93.
          14. Jimenez E, Martínez A, Aliouat el M, Caballero J, Dei-Cas E, Gargallo-Viola D. Therapeutic efficacies of GW471552 and GW471558, two new azasordarin derivatives, against pneumocystosis in two immunosuppressed-rat models.. Antimicrob Agents Chemother 2002 Aug;46(8):2648-50.
          15. Alonso S, Reveneau N, Pethe K, Locht C. Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.. Infect Immun 2002 Aug;70(8):4142-7.
          16. Durand-Joly I, Aliouat el M, Recourt C, Guyot K, François N, Wauquier M, Camus D, Dei-Cas E. Pneumocystis carinii f. sp. hominis is not infectious for SCID mice.. J Clin Microbiol 2002 May;40(5):1862-5.
          17. Alonso S, Pethe K, Mielcarek N, Raze D, Locht C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.. Infect Immun 2001 Oct;69(10):6038-43.
          18. Grangette C, Müller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.. Infect Immun 2001 Mar;69(3):1547-53.
          19. Stringer JR, Keely SP. Genetics of surface antigen expression in Pneumocystis carinii.. Infect Immun 2001 Feb;69(2):627-39.
            doi: 10.1128/IAI.69.2.627-639.2001pubmed: 11159949google scholar: lookup
          20. Choi MH, Chung BS, Chung YB, Yu JR, Cho SR, Hong ST. Purification of a 68-kDa cysteine proteinase from crude extract of Pneumocystis carinii.. Korean J Parasitol 2000 Sep;38(3):159-66.
            doi: 10.3347/kjp.2000.38.3.159pubmed: 11002651google scholar: lookup